Cullinan Therapeutics Reports $53.7 Million Q2 Loss, Missing Analyst Expectations
核心洞察
Cullinan Therapeutics, Inc. (CGEM) reported a second-quarter loss of $53.7 million, or 81 cents per share, for the Cambridge, Massachusetts-based company.
The results missed Wall Street expectations, as five analysts surveyed by Zacks Investment Research had forecast a loss of 71 cents per share.
The earnings report reflects the company's quarterly financial performance and its position relative to consensus analyst estimates.
Cullinan Therapeutics, Inc. (CGEM) reported a loss of $53.7 million in its second quarter, the Cambridge, Massachusetts-based company announced Thursday. On a per-share basis, the company posted a loss of 81 cents.
The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research had projected a loss of 71 cents per share, meaning the company's reported loss was wider than consensus forecasts.
The quarterly report provides a snapshot of the company's recent financial performance, reflecting the costs and expenditures associated with its operations during the period. The earnings data was generated by Automated Insights using information from Zacks Investment Research.